A follow-up study extended this strategy by generating anti-CD3 and anti-HER2-expressing EVs that enhanced T cell activation while targeting HER2-positive HCC1954 breast cancer tumors [157]. This evidence concerns the gene ERBB2 and breast carcinoma.